Human Genome Sciences signs supply deal for Benlysta with Lonza
Written on July 16, 2010
Rockville-based Human Genome Sciences Inc., which is seeking approval to sell its new treatment for lupus in the U.S. and Europe, is taking steps to make sure it will have plenty of supply.
Human Genome (NASDAQ: HGSI) said Tuesday that it had reached an agreement with Swiss firm Lonza to produce future supplies of Benlysta, its lupus treatment being developed in partnership with GlaxoSmithKline.
Terms of the manufacturing agreement were not disclosed.
“We are enthusiastic about supporting the future production of Benlysta with our cutting-edge capabilities and expertise in biopharmaceutical manufacturing,” said Lonza Custom Manufacturing COO Dr payday loan. Stephan Kutzer. “Working on such an important new drug for lupus patients will be very rewarding and the basis for a long-term, collaborative relationship with HGS.”
Human Genome and Glaxo are awaiting word from the Food and Drug Administration and the European Medicines Agency on applications submitted in June to market Benlysta for the treatment of systemic lupus erythematosus.
Filed in: online.